PTG-007

The European Medicines Agency's Pediatric Committee has issued a positive opinion on PolTREG's Pediatric Investigation Plan for PTG-007, expanding the eligible age range from 6-16 to 3-18 years for pre-symptomatic type 1 diabetes treatment.

PolTREG has launched a Phase 2 clinical trial evaluating PTG-007, a Treg cell therapy, in children with presymptomatic type 1 diabetes (T1D).

PolTREG has launched a Phase 2, placebo-controlled clinical trial of PTG-007, a Treg cell therapy, in children with presymptomatic type 1 diabetes (T1D).

PolTREG initiates preclinical study of CAR-Treg cells for neuroinflammatory diseases, including multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).

PolTREG's PTG-007 cell therapy induced clinical remission in some patients with type 1 diabetes for up to 12 years, showcasing its long-term potential.